Better than approved therapy Pfizer JAK1 inhibitor for eczema to reach phase 3 clinical endpoint

On August 30, 2021, Pfizer announced that the Phase 3 clinical trial of the oral JAK1 inhibitor abrocitinib, JADE DARE, has reached its common primary and critical secondary efficacy endpoints

Abrocitinib is an oral JAK1 inhibitor

The 26-week, randomized, double-blind, double-simulated, active-controlled, multi-center JADE DARE trial aims to compare the efficacy and safety of abrocitinib and approved IL-4Rα antibody therapy in the treatment of patients with atopic dermatitis

▲The molecular structure of Abrocitinib (picture source: Edgar181, Public domain, via Wikimedia Commons)

In terms of safety, the percentage of adverse events in the abrocitinib group was higher than that in the active control group

Atopic dermatitis is a chronic skin disease characterized by skin inflammation and skin barrier defects.

The complete results of JADE DARE will be submitted to future scientific conferences and published in medical journals

Reference materials:

[1] Positive Top-Line Results From Pfizer'S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.

(The original text has been deleted)